A Total of 234 Patients With Acute Coronary Syndrome Who Will Undergo OPCAB. Clinical Trial
Periprocedural treatment with high-dose statins is known to have cardioprotective and
pleiotropic effects, such as anti-thrombotic and anti-inflammatory actions.
-Objective: to determine whether preoperative rosuvastatin loading is independently
associated with reduced myocardial ischemia and clinical outcomes in patients with stable
angina undergoing isolated off-pump coronary bypass (OPCAB) in patients with acute coronary
syndrome.
Study design
- Prospective, double-blinded, single-center study of each 117 subjects enrolled
- Subjects with acute coronary syndrome who meet all inclusion and exclusion criteria
will be enrolled preoperatively.
- Eligible subjects will be randomized 1:1 to A) High-dose rosuvastatin (n=117) vs. B)
Placebo (n=117).
- The amount of preoperative administration of high-dose rosuvastatin will be 60mg of a
total
- All subjects will undergo OPCAB procedure. - The primary and secondary endpoints will
be compared at 30 days and 2 years postoperatively between two groups
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care